Figure 1


CLS103 LVT-murinCLDN18.2
Rituximab + Isotype control
IMAB362 + Isotype control
Rituximab + anti-mPD-1
IMAB362 + anti-mPD-1
n=12
Tumor volume MEAN ± SE (mm³)
Days after first administration
CLS103 LVT-murinCLDN18.2 Day14
n=12
# #
#
Rituximab + Isotype
IMAB362 + Isotype
Rituximab + anti-mPD-1
IMAB362 + anti-mPD-1

Figure 2

Figure 2A



Figure 2B



Figure 3


Group1: Rituximab / Isotype
CR 1/12
Tumor volume (mm3)
Days after first administration
Group2:IMAB362 / Isotype
CR 2/12
Tumor volume (mm3)
Days after first administration
Group3:Rituximab / anti-mPD-1 Ab
CR 1/12
Tumor volume (mm3)
Days after first administration
Group4:IMAB362 / anti-mPD-1 Ab
CR 6/12
Tumor volume (mm3)
Days after first administration

Figure 4


CLS103 LVT-murinCLDN18.2
Rituximab/Isotype
IMAB362/Isotype
Rituximab/anti-mPD-1 Ab
IMAB362/anti-mPD-1 Ab
TGI%
40%
87%
**
*
Tumor volume MEAN ± SEM (mm³)
Days after first administration
0
500
1000
1500
0
5
10
15
20

Figure 5


CLS-103 LVT-murinCLDN18.2
Tumor volume MEAN ± SEM (mm³)
800
600
400
200
0
0
5
10
15
Days after first administration
*
Rituximab/Isotype
IMAB362/Isotype
Rituximab/anti-mCTLA-4 Ab
IMAB362/anti-mCTLA-4 Ab
day14
TGI% (TRR%)
72%
87%
(3%)
Tumor volume (mm³)
1500
1000
500
0
*
Rituximab/Isotype
IMAB362/Isotype
Rituximab/anti-mCTLA-4 Ab
IMAB362/anti-mCTLA-4 Ab

Figure 6


Group1:Rituximab / Isotype
Group2:IMAB362 / Isotype
Group3:Rituximab / anti-mCTLA-4 Ab
Group4:IMAB362 / anti-mCTLA-4 Ab
Tumor volume (mm3)
Days after first administration
0
500
1000
0
5
10
15

Figure 7


CLS-103 LVT-murinCLDN18.2
Tumor volume MEAN ± SEM (mm3)
800
600
400
200
0
0
5
10
15
Days after first administration
Rituximab/Isotype
IMAB362/Isotype
Rituximab/anti-mPD-L1 Ab
IMAB362/anti-mPD-L1 Ab
*
**
day14
TGI% (TRR%)
60%
62%
(13%)
Tumor volume (mm3)
1000
500
0
Rituximab/Isotype
IMAB362/Isotype
Rituximab/anti-mPD-L1 Ab
IMAB362/anti-mPD-L1 Ab

Figure 8


Group1:Rituximab / Isotype
n=11
Group2:IMAB362 / Isotype
n=12
Group3:Rituximab / anti-mPD-L1 Ab
n=12
Group4:IMAB362 / anti-mPD-L1 Ab
n=12
Tumor volume (mm3)
1000
500
0
0
5
10
15
Days after first administration